The new crown vaccine has a second generation? Vaccine R & D specialist response

At the successful serviceman just closed, the second generation new crown vaccine debut.

According to reports, the new generation of new generation of new generation of Chinese biological research and development, which not only has inactivated vaccines for variants, but also a broad-spectrum recombinant protein vaccine, independently developed mRNA vaccine.

Why develop the second generation new crown vaccine? Is it now a generation of vaccines? When can the second-generation new crown vaccine be listed? Which step is going now? On September 7, the State Council’s joint defense mechanism held a press conference, the head of the working group of the scientific research project, and Zheng Zhongwei, director of the National Health and Health Committee Science and Technology Development Center, made an authority response to these issues. Is a vaccine still used? Data from the press conference show that as of September 6th, the national accumulated reports were inoculated with a new crown virus vaccine, and the number of people who completed the whole process was 91,69.72 million.

The 12-17 years old, the population has been vaccinated by 62.228 million dosage times.

So, do you still use a vaccine for a variant strain for new crown viruses? Zheng Zhongwei believes that the effectiveness should be certified to the results of the real world, he said: my country’s new crown is inactivated, and the vaccination of larger-scale people has been carried out globally. It has also been vaccinated by 2 billion factories in China. There are many real-world research data.

These findings show that both domestic or foreign countries have a certain effect on preventing infection; there is a clear effect on the infection, and there is a significant effect on preventing severe and death. Zheng Zhongwei emphasized: "Even in the case of viral variability, especially Delta strain, is also widely popular.

"Whether it is in Beijing or Guangzhou’s last round of epidemic, the vaccination effect is obvious.

The study of Zhongnan Mountain is aimed at the study of Guangdong ‘s epidemic (the main Delta strain), and after inoculation of the two doses vaccinated, the protected effect of Semi-illness reached 70%, and the protective effect of severe achievement reached 100%.

Why do I need two generations of vaccines? Since a generation of vaccines are still effective, why should I develop second-generation vaccine? "Although the variation of new crown viruses is relatively stable so far, there is no fundamental variation, we still need to take precautions.

"Zheng Zhongwei said, it is prepared, even if there is a serious variation in the future, it fully escapes the prevention of the current vaccine, and can quickly develop and scale the new vaccine, which is unpredictable. Recently, American disease control The latest research on the Prevention Center (CDC) shows that with the dominant position of Delta variand strains in new crown viruses, the effectiveness of American new crown virus vaccine has dropped from previous 91% to 66%.

The results of this real world have also made a broad spectrum and a multi-priced second-generation vaccine. In addition to early in vaccine, the relevant review approval system is also actively deployed. Zheng Zhongwei introduced that my country’s relevant agencies have also launched a formulation of the principles of variants of vaccine review approval guidelines, and made some basic arrangements for the review approval. how is the progress? For new crown virus variants, each vaccine R & D unit has been developing a series of work of various variable strains since the occurrence of the epidemic, especially the variability.

Zheng Zhongwei introduced that the vaccine research and development unit in my country has carried out the research of gamma straam and Delta strain. At present, the pre-clinical study has been completed, and some units have submitted the application information of clinical trials to the Drug Review Center. . The second is to carry out research on broad-spectrum or multivalent recombinant protein vaccine against different variants, and some units have also rolled the application information for clinical trials to the Drug Review Center. The third is to carry out research and development of adenopathy vessel vaccine and nucleic acid vaccine in Beta strain, Delta strain. Some units have completed experiments with animal effectiveness and safety, and are preparing to declare clinical trials. (Editor: Jia Zejuan, Zhong Ming).